Edesa Biotech Inc
Follow $EDSA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $EDSA by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is EDSA moving today?
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
EDSA overview
Related filings and maps
Congress activity in EDSA
No receipt-qualified filings found.
EDSA contract awards, year to date.
Public federal awards linked to this ticker.
EDSA lobbying filings, year to date.
Registered lobbying filings matched to Edesa Biotech Inc.